Homozygous deletions and recurrent amplications implicate new genes involved in prostate cancer

Neoplasia

Volumn 10, Issue 8, 2008, Pages 897-907

  Liu, Wennuan ^a   Xie, Chunmei Carol ^a   Zhu, Yi ^a   Li, Tao ^a   Sun, Jishan ^a   Cheng, Yu ^a   Ewing, Charles M ^b   Dalrymple, Sue ^b   Turner, Aubrey R ^a   Sun, Jielin ^a   Isascs, John T ^b   Chang, Bao Li ^a   Zheng, Siqun Lilly ^a   Isaacs, William B ^b,c   Xu, Jianfeng ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA;

ARTICLE; BNIP3L GENE; CANCER RECURRENCE; CARCINOGENESIS; CONTROLLED STUDY; GENE AMPLIFICATION; GENE DELETION; GENE IDENTIFICATION; GENE LOCATION; GENE MUTATION; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN CELL; PPP2R2A GENE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR GENE;

EID: 48249153087     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.08428     Document Type: Article

References (41)

1. Bernardino J, Bourgeois CA, Muleris M, Dutrillaux AM, Malfoy B, and Dutrillaux B (1997). Characterization of chromosome changes in two human prostatic carcinoma cell lines (PC-3 and DU145) using chromosome painting and comparative genomic hybridization. Cancer Genet Cytogenet 96, 123-128.
2. Nupponen NN, Hyytinen ER, Kallioniemi AH, and Visakorpi T (1998). Genetic alterations in prostate cancer cell lines detected by comparative genomic hybridization. Cancer Genet Cytogenet 101, 53-57.
3. Virgin JB, Hurley PM, Nahhas FA, Bebchuk KG, Mohamed AN, Sakr WA, Bright RK, and Cher ML (1999). Isochromosome 8q formation is associated with 8p loss of heterozygosity in a prostate cancer cell line. Prostate 41, 49-57.
4. Aurich-Costa J, Vannier A, Gregoire E, Nowak F, and Cherif D (2001). IPM-FISH, a new M-FISH approach using IRS-PCR painting probes: application to the analysis of seven human prostate cell lines. Genes Chromosomes Cancer 30, 143-160.
5. Clark J, Edwards S, Feber A, Flohr P, John M, Giddings I, Crossland S, Stratton MR, Wooster R, Campbell C, et al. (2003). Genome-wide screening for complete genetic loss in prostate cancer by comparative hybridization onto cDNA microarrays. Oncogene 22, 1247-1252.
6. van Bokhoven A, Caires A, Maria MD, Schulte AP, Lucia MS, Nordeen SK, Miller GJ, and Varella-Garcia M (2003). Spectral karyotype (SKY) analysis of human prostate carcinoma cell lines. Prostate 57, 226-244.
7. Lieberfarb ME, Lin M, Lechpammer M, Li C, Tanenbaum DM, Febbo PG, Wright RL, Shim J, Kantoff PW, Loda M, et al. (2003). Genome-wide loss of heterozygosity analysis from laser capture microdissected prostate cancer using single nucleotide polymorphic allele (SNP) arrays and a novel bioinformatics platform dChipSNP. Cancer Res 63, 4781-4785.
8. Zhao H, Kim Y, Wang P, Lapointe J, Tibshirani R, Pollack JR, and Brooks JD (2005). Genome-wide characterization of gene expression variations and DNA copy number changes in prostate cancer cell lines. Prostate 63, 187-197.
9. Paris PL, Hofer MD, Albo G, Kuefer R, Gschwend JE, Hautmann RE, Fridyland J, Simko J, Carroll PR, Rubin MA, et al. (2006). Genomic profiling of hormone-naive lymph node metastases in patients with prostate cancer. Neoplasia 8, 1083-1089.
10. Watson SK, deLeeuw RJ, Horsman DE, Squire JA, and Lam WL (2007). Cytogenetically balanced translocations are associated with focal copy number alterations. Hum Genet 120, 795-805.
11. Kim JH, Dhanasekaran SM, Mehra R, Tomlins SA, Gu W, Yu J, Kumar-Sinha C, Cao X, Dash A, Wang L, et al. (2007). Integrative analysis of genomic aberrations associated with prostate cancer progression. Cancer Res 67, 8229-8239.
12. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, et al. (2005). Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310, 644-648.
13. Tomlins SA, Laxman B, Dhanasekaran SM, Helgeson BE, Cao X, Morris DS, Menon A, Jing X, Cao Q, Han B, et al. (2007). Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 448, 595-599.
14. Liu W, Chang B, Sauvageot J, Dimitrov L, Gielzak M, Li T, Yan G, Sun J, Sun J, Adams TS, et al. (2006). Comprehensive assessment of DNA copy number alterations in human prostate cancers using Affymetrix 100K SNP mapping array. Genes Chromosomes Cancer 45, 1018-1032.
15. Liu W, Ewing CM, Chang BL, Li T, Sun J, Turner AR, Dimitrov L, Zhu Y, Sun J, Kim JW, et al. (2007). Multiple genomic alterations on 21q22 predict various TMPRSS2/ERG fusion transcripts in human prostate cancers. Genes Chromosomes Cancer 46, 972-980.
16. Hayward SW, Dahiya R, Cunha GR, Bartek J, Despande N, and Narayan P (1995). Establishment and characterization of an immortalized but non-tumorigenic human prostate epithelial cell line: BPH-1. In Vitro 31A, 14-24.
17. Sramkoski R, Pretlow TG, Giaconia J, Pretlow TP, Schwartz S, Sy MS, Marengo S, Rhim J, Zhang D, and Jacobberger J (1999). A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell Dev Biol Anim 35, 403-409.
18. Koochekpour S, Maresh GA, Katner A, Parker-Johnson K, Lee TJ, Hebert FE, Kao YS, Skinner J, and Rayford W (2004). Establishment and characterization of a primary androgen-responsive African-American prostate cancer cell line, E006AA. Prostate 60, 141-152.
19. Yasunaga Y, Nakamura K, Ewing MC, Isaacs WB, Hukku B, and Rhim JS (2001). A novel human cell culture model for the study of familial prostate cancer. Cancer Res 61, 5969-5973.
20. Hoehn W, Schroeder FH, Reimann JF, Joebsis AC, and Hermanek P (1980). Human prostatic adenocarcinoma: some characteristics of a serially transplantable line in nude mice (PC 82). Prostate 1, 95-104.
21. Romijn JC, Verkoelen CF, and Schroeder FH (1984). Determination of the growth rate of human prostatic cells in primary culture by a morphometric technique. Cell Biol Int Rep 8, 363-371.
22. Nannya Y, Sanada M, Nakazaki K, Hosoya N, Wang L, Hangaishi A, Kurokawa M, Chiba S, Bailey DK, Kennedy GC, et al. (2005). A robust algorithm for copy number detection using high-density oligonucleotide single nucleotide polymorphism genotyping arrays. Cancer Res 65, 6071-6079.
23. Lin M, Wei LJ, Sellers WR, Lieberfarb M, Wong WH, and Li C (2004). dChipSNP: significance curve and clustering of SNP-array-based loss-of-heterozygosity data. Bioinformatics 20, 1233-1240.
24. Chang BL, Liu W, Sun J, Dimitrov L, Li T, Turner AR, Zheng SL, Isaacs WB, and Xu J (2007). Integration of somatic deletion analysis of prostate cancers and germline linkage analysis of prostate cancer families reveals two small consensus regions for prostate cancer genes at 8p. Cancer Res 67, 4098-4103.
25. Borre M, Høyer M, Nerstrøm B, and Overgaard J (1998). DNA ploidy and survival of patients with clinically localized prostate cancer treated without intent to cure. Prostate 36, 244-249.
26. Mellor HR and Harris AL (2007). The role of the hypoxia-inducible BH3-only proteins BNIP3 and BNIP3L in cancer. Cancer Metastasis Rev 26, 553-566.
27. Fei P, Wang W, Kim SH, Wang S, Burns TF, Sax JK, Buzzai M, Dicker DT, McKenna WG, Bernhard EJ, et al. (2004). Bnip3L is induced by p53 under hypoxia, and its knockdown promotes tumor growth. Cancer Cell 6, 597-609.
28. Niedergethmann M, Alves F, Neff JK, Heidrich B, Aramin N, Li L, Pilarsky C, Grutzmann R, Allgayer H, Post S, et al. (2007). Gene expression profiling of liver metastases and tumour invasion in pancreatic cancer using an orthotopic SCID mouse model. Br J Cancer 97, 1432-1440.
29. Calvisi DF, Ladu S, Gorden A, Farina M, Lee JS, Conner EA, Schroeder I, Factor VM, and Thorgeirsson SS (2007). Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J Clin Invest 117, 2713-2722.
30. Jin Y, Mertens F, Kullendorff CM, and Panagopoulos I (2006). Fusion of the tumor-suppressor gene CHEK2 and the gene for the regulatory subunit B of protein phosphatase 2 PPP2R2A in childhood teratoma. Neoplasia 8, 413-418.
31. Jarrard DF, Bova GS, Ewing CM, Pin SS, Nguyen SH, Baylin SB, Cairns P, Sidransky D, Herman JG, and Isaacs WB (1997). Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer. Genes Chromosomes Cancer 19, 90-96.
32. Mangold KA, Takahashi H, Brandigi C, Wada T, Wakui S, Furusato M, Boyd J, Chandler FW, and Allsbrook WC Jr (1997). p16 (CDKN2/MTS1) gene deletions are rare in prostatic carcinomas in the United States and Japan. J Urol 157, 1117-1120.
33. Heidenreich B, Heidenreich A, Sesterhenn A, Srivastava S, Moul JW, and Sesterhenn IA (2000). Aneuploidy of chromosome 9 and the tumor suppressor genes p16(INK4) and p15(INK4B) detected by in situ hybridization in locally advanced prostate cancer. Eur Urol 38, 475-482.
34. Komiya A, Suzuki H, Aida S, Yatani R, and Shimazaki J (1995). Mutational analysis of CDKN2 (CDK4I/MTS1) gene in tissues and cell lines of human prostate cancer. Jpn J Cancer Res 86, 622-625.
35. Chen W, Weghorst CM, Sabourin CL, Wang Y, Wang D, Bostwick DG, and Stoner GD (1996). Absence of p16/MTS1 gene mutations in human prostate cancer. Carcinogenesis 17, 2603-2607.
36. Konishi N, Nakamura M, Kishi M, Nishimine M, Ishida E, and Shimada K (2002). Heterogeneous methylation and deletion patterns of the INK4a/ARF locus within prostate carcinomas. Am J Pathol 160, 1207-1214.
37. Yamamoto M, Metoki R, and Yamamoto F (2004). Systematic multiplex polymerase chain reaction and reverse transcription-polymerase chain reaction analyses of changes in copy number and expression of proto-oncogenes and tumor suppressor genes in cancer tissues and cell lines. Electrophoresis 25, 3349-3356.
38. Zanke BW, Greenwood CM, Rangrej J, Kustra R, Tenesa A, Farrington SM, Prendergast J, Olschwang S, Chiang T, Crowdy E, et al. (2007). Genome-wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24. Nat Genet 39, 989-994.
39. Zheng SL, Sun J, Cheng Y, Li G, Hsu FC, Zhu Y, Chang BL, Liu W, Kim JW, Turner AR, et al. (2007). Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans. J Natl Cancer Inst 99, 1525-1533.
40. Korenchuk S, Lehr JE, MClean L, Lee YG, Whitney S, Vessella R, Lin DL, and Pienta KJ (2001). VCaP, a cell-based model system of human prostate cancer. In Vivo 15, 163-168.
41. Sun J, Liu W, Adams TS, Sun J, Li X, Turner AR, Chang B, Kim JW, Zheng SL, Isaacs WB, et al. (2007). DNA copy number alterations in prostate cancers: a combined analysis of published CGH studies. Prostate 67, 692-700.